News

Over the last 4 weeks there has been an 80% increase in the continent and the Delta variant is the large cause according to the World Health Organization (WHO).

A study looked at the efficacy of the Pfizer-BioNTech mRNA COVID-19 vaccine in a high-risk national population within a real-world setting.

Patients failed to respond to currently available drugs in initial documented instances of spread.

FluGen announced its vaccine candidate, Bris2007 M2SR, induced neutralizing antibodies against infection and illness following a challenge with an antigenically distinct virus.

Ownership language showed an additional boost in appointment and vaccination rates.

Fever was found to not be an early feature of disease.

An early warning system could help significantly help health systems and public officials to prepare.

Three HIV screening strategies identified comparable numbers of new HIV diagnoses, a new study found.

A seven-day course of antibiotics was as effective as 14 days in treating urinary tract infection in afebrile men.

Patients given a 600 mg injection of cabotegravir still had detectable levels of the drug in plasma, tissues, and fluids for 12 weeks.

What are the efforts being made with antibiotic stewardship and treatments, and what areas in clinical care do medical professionals want to see improvements.

More and more evidence is pointing towards persistent neuropsychiatric symptoms in people who had the disease.

The study found that ¾ of the cases occurred in fully vaccinated individuals.

Reasons given for not vaccinating were safety issues and low risk for infection.

A conversation with Anna Legreid Dopp, Pharm. D.

With new mask guidance comes questions and confusion, especially with the new strain of COVID-19 and those who have been vaccinated.

A clinical decision support (CDS) strategy including a default influenza vaccine order for eligible patients, a nursing script using a presumptive strategy, and education for clinicians, was associated with significant improvement in vaccination rates among hospitalized children, a new study showed.

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

The company is planning to use its mRNA platform to develop the vaccine for malaria, which is the same successful technology it harnessed for its COVID-19 vaccine.

With its latest earnings report showing the financial impact of the vaccine, the Delta variant becoming the dominant strain in the US, and concerns of waning immunity, the company believes there is evidence for an additional booster shot.

A new report based on wearable technology finds it takes an average of 79 days for patients’ resting heart rates to return to normal following COVID-19 infection.

Commonly reported issues included delirium, encephalopathies and psychiatric complications.

Public information campaigns may potentially boost rates of vaccination.

As much as 2% of vaccine recipients have reported anaphylaxis following their first shot.

A recent study of sexually active young women in Africa found that initiation of HIV preexposure prophylaxis (PrEP) was high at 95% and one-fifth showed high adherence at 6 months.

Asymptomatic and symptomatic COVID-19 cases among health care personnel were reduced after vaccination despite surge in infected patients.

The agency is expected to make a statement later today on masking recommendations.

The nasal mucosa was seen to be an essential determinant of overall disease trajectory.

The framework could help officials assess the true burden of disease in certain areas.

In a small study, the newly FDA approved antifungal demonstrated “clinical activity” against the emerging pathogen.